As the Australian market navigates through December, recent disruptions like the ASX announcements outage have highlighted some of the operational challenges facing investors, while fluctuations in sectors such as energy and materials reflect broader economic dynamics. In this environment, identifying promising small-cap stocks requires a keen eye for companies that can demonstrate resilience and growth potential amidst market volatility.

Top 10 Undiscovered Gems With Strong Fundamentals In Australia

Name	Debt To Equity	Revenue Growth	Earnings Growth	Health Rating
Fiducian Group	NA	10.00%	9.57%	★★★★★★
Joyce	NA	9.93%	17.54%	★★★★★★
Hearts and Minds Investments	NA	56.27%	59.19%	★★★★★★
Spheria Emerging Companies	NA	-1.31%	0.28%	★★★★★★
Euroz Hartleys Group	NA	1.82%	-25.32%	★★★★★★
Focus Minerals	NA	75.35%	51.34%	★★★★★★
Energy World	NA	-47.50%	-44.86%	★★★★★☆
Zimplats Holdings	5.44%	-9.79%	-42.03%	★★★★★☆
Australian United Investment	1.90%	5.23%	4.56%	★★★★☆☆
Reef Casino Trust	19.84%	6.96%	10.88%	★★★★☆☆

Click here to see the full list of 57 stocks from our ASX Undiscovered Gems With Strong Fundamentals screener.

We’ll examine a selection from our screener results.

Cogstate

Simply Wall St Value Rating: ★★★★★★

Overview: Cogstate Limited is a neuroscience solutions company focused on developing, validating, and commercializing digital brain health assessments globally with a market cap of A$418.76 million.

Operations: Cogstate generates revenue primarily from its Clinical Trials segment, which accounts for $50.58 million, while the Healthcare segment contributes $2.51 million.

Cogstate, a neuroscience tech firm known for digital brain health assessments, is carving out growth through its Medidata partnership and AI-driven products. This collaboration is set to broaden Cogstate’s reach into new CNS indications and geographies, potentially boosting its contract pipeline. The company’s earnings grew 86% last year, surpassing the Healthcare Services industry’s 18.5%, with a P/E ratio of 27x below the industry average of 36.2x. Despite being debt-free now compared to a 16.4% debt-to-equity ratio five years ago, it faces challenges like regulatory hurdles and competitive pressures from larger digital health players.

• Cogstate’s strategic partnership with Medidata enhances its market reach and contract pipeline. Click here to explore the full narrative on Cogstate’s growth potential.

ASX:CGS Debt to Equity as at Dec 2025GenusPlus Group

Simply Wall St Value Rating: ★★★★★★

Overview: GenusPlus Group Ltd specializes in the installation, construction, and maintenance of power and communication systems in Australia with a market cap of A$1.15 billion.

Operations: GenusPlus Group Ltd generates revenue primarily from three segments: Infrastructure (A$405.10 million), Energy & Engineering (A$224.06 million), and Services (A$122.11 million).

GenusPlus Group, a nimble player in Australia’s energy sector, is poised for growth with its strategic focus on renewable energy and grid upgrades. The company boasts a robust pipeline of diverse projects, reducing geographic risk while venturing into high-margin areas like battery storage systems. Over the past year, earnings surged by 83.6%, outpacing the construction industry’s 6.5% growth rate. With more cash than total debt and positive free cash flow reaching A$69 million recently, GenusPlus seems financially sound. The recent addition of Tony Narvaez as a director brings valuable industry expertise to navigate future challenges and opportunities effectively.

• GenusPlus Group is expanding into high-margin battery energy storage systems, enhancing profit margins. Click here to explore the full narrative on GenusPlus Group’s strategic growth.

ASX:GNP Earnings and Revenue Growth as at Dec 2025Omni Bridgeway

Simply Wall St Value Rating: ★★★★★☆

Overview: Omni Bridgeway Limited, along with its subsidiaries, offers dispute and litigation finance services across multiple regions including Australia, the United States, Canada, Latin America, Asia, New Zealand, Europe, the Middle East, and Africa with a market capitalization of A$451.20 million.

Operations: Omni Bridgeway generates revenue primarily from funding and providing services related to legal dispute resolution, amounting to A$87.77 million.

Omni Bridgeway, a notable player in the financial litigation space, has recently turned profitable, boasting a debt to equity ratio reduction from 18.7% to 2.3% over five years. Its price-to-earnings ratio stands at an attractive 1.3x compared to the Australian market’s 22x, indicating potential value for investors. Despite earnings forecasted to decline by an average of 148% annually over the next three years, revenue is expected to grow by approximately 24%. The company enjoys high-quality non-cash earnings and more cash than total debt, suggesting financial stability amidst industry challenges.

• Click here to discover the nuances of Omni Bridgeway with our detailed analytical health report.

• Gain insights into Omni Bridgeway’s historical performance by reviewing our past performance report.

ASX:OBL Earnings and Revenue Growth as at Dec 2025Summing It All Up

• Unlock our comprehensive list of 57 ASX Undiscovered Gems With Strong Fundamentals by clicking here.

• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St’s portfolio, where intuitive tools await to help optimize your investment outcomes.

• Join a community of smart investors by using Simply Wall St. It’s free and delivers expert-level analysis on worldwide markets.

Seeking Other Investments?

• Explore high-performing small cap companies that haven’t yet garnered significant analyst attention.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ASX:CGS ASX:GNP and ASX:OBL.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com